

FLUVOXAMINE IS A POTENT INHIBITOR OF CYTOCHROME P4501A2

KIM BRØSEN,*† ERIK SKJELBO,* BIRGITTE B. RASMUSSEN,* HENRIK E. POULSEN‡ and
STEFFEN LOFT‡

*Department of Clinical Pharmacology, Institute of Medical Biology, Odense University and

‡Department of Pharmacology, University of Copenhagen, Denmark

(Received 19 October 1992; accepted 18 December 1992)

Abstract—Fluvoxamine is a new antidepressant and selectively inhibits serotonin reuptake (SSRI). The present study demonstrates that fluvoxamine is a very potent inhibitor of the high-affinity O-deethylation of phenacetin, which is catalysed by cytochrome P4501A2 (CYP1A2), in microsomes from three human livers. Thus, the apparent inhibitor constant of fluvoxamine, K_i , ranged from 0.12 to 0.24 μM . Seven other SSRIs, citalopram, *N*-desmethylocitalopram, fluoxetine, norfluoxetine, paroxetine, sertraline and litoxetine either did not inhibit or were weak inhibitors of the O-deethylation of phenacetin. Our findings explain the mechanism of the pharmacokinetic interactions between fluvoxamine and drugs that are metabolized by CYP1A2, e.g. theophylline and imipramine.

Fluvoxamine is a new antidepressant, a selective serotonin reuptake inhibitor (SSRI§), which is eliminated primarily via oxidation in the liver [1]. Fluvoxamine is a very potent inhibitor of one of the cytochrome P450s (CYP1A2, CYP2C, CYP2D6 and CYP3A4 nomenclature as used by Nebert *et al.* [2]) which catalyse the *N*-demethylation of imipramine in human liver microsomes with an apparent inhibitor constant, K_i , of 0.14 μM [3]. The apparent K_i of fluvoxamine for inhibition of the 2-hydroxylation of imipramine, a process which is catalysed by the sparteine/debrisoquine oxygenase CYP2D6 [2], was 4 μM [3]. The *N*-demethylation of imipramine is partially determined by the mephenytoin oxidation polymorphism *in vivo*, suggesting a role of a P450 in the 2C subfamily for this reaction [4]. However, the role of 2C isozymes was not confirmed *in vitro* [3, 5]. In microsomes from nine human livers (HLs) there was a statistically significant, positive correlation between the content of two other isozymes of cytochrome P450, the CYP1A2 and CYP3A4 [2] and the maximal velocity of *N*-desmethylimipramine formation (H. Kroemer, personal communication). This finding has been confirmed in an independent study [5]. Cigarette smoking induces the levels of CYP1A2 in HL [6] and clinical studies have suggested that the *N*-demethylation of imipramine proceeds more rapidly in smokers than in non-smokers [7]. Thus, both the *in vitro* and the *in vivo* data suggest that CYP1A2 is an important enzyme for the *N*-demethylation of imipramine, and when we combined the results of the various studies we suspected that fluvoxamine might be a potent inhibitor of the human CYP1A2.

Theophylline is also metabolized by CYP1A2 [8], and three case reports suggest inhibition of theophylline metabolism by fluvoxamine [9–11], lending further support to this notion. On this basis a study was performed on the effects of fluvoxamine on the high-affinity O-deethylation of phenacetin, a well established marker reaction for the CYP1A2 function in human liver microsomes [6, 12].

MATERIALS AND METHODS

Chemicals. Phenacetin and paracetamol were obtained from Hopkins and Williams Ltd (Chadwell Heath, U.K.). Fluvoxamine: Duphar, B.V. (Weesp, Holland). Citalopram and *N*-desmethylocitalopram: H. Lundbeck A/S (Denmark). Fluoxetine and norfluoxetine: Eli Lilly A/S (Denmark). Sertraline: Pfizer Inc. (U.S.A.). Litoxetine: Synthelabo (France). Paroxetine: Novo-Nordisk (Denmark).

Other chemicals were of high analytical grade and supplied by Merck (Darmstadt, Germany).

Liver microsomes. Whole HLs were obtained from three kidney donor patients shortly after circulatory arrest. The livers were immediately cut into slices, frozen in dry ice and stored at -80°C . Microsomes were prepared by a standard technique [13], and the protein concentration was measured by the method of Lowry *et al.* [14].

Incubation conditions. Microsomes were incubated in a final incubation volume of 500 μL in a disodium phosphate buffer (100 mM; pH 7.4) using 100 μg of microsomal protein. Stock solutions of 50 μL phenacetin and 50 μL of fluvoxamine were pre-incubated for 5 min at room temperature. Microsomes from the three livers were incubated with phenacetin in final concentrations of 1, 2.5, 5, 10 and 100 μM and fluvoxamine in final concentrations of 0, 0.1, 0.25, 0.5, 1.0, 5.0, 10, 20, 40 and 100 μM . The reaction was started by adding 50 μL of an NADPH-generating system (concentrations in microsomal suspension: isocitrate dehydrogenase, 1 U/mL, NADPN₂, 1 mM, isocitrate, 5 mM,

† Corresponding author: Kim Brøsen, Department of Clinical Pharmacology, Institute of Medical Biology, Odense University, Winsløwparken 19, DK-5000 Odense C, Denmark. Tel. (45) 66 15 86 00, ext. 4751; FAX (45) 66 13 34 79.

§ Abbreviations: HL, human liver; SSRI, selective serotonin reuptake inhibitors.

Table 1. Inhibition* of the formation of paracetamol by fluvoxamine from three HLs

	V_{\max} (nmol/mg/hr)	K_m (μ M)	K_i (μ M)	L^\dagger (μ L/mg/hr)
HL1	202 (196–209)	57 (55–60)	0.18 (0.11–0.27)	13.2
HL2	96 (89–101)	47 (43–53)	0.24 (0.17–0.27)	6.1
HL3	27 (18–30)	14 (10–26)	0.12 (0.05–0.18)	3.1

* V_{\max} , K_m , K_i refer to the high affinity side (Eqn 1).

A complete set of data were determined at each of the phenacetin concentrations of 1, 2.5, 5, 10 and 100 μ M, and the means (range) of the five separate determinations are given for each constant in each of the three livers.

† Determined according to Eqn 1 at a phenacetin concentration of 100 μ M.

Table 2. Effects on the formation of paracetamol by eight SSRIs in HL1

SSRI	IC_{50} (μ M)
Fluvoxamine	0.2
Citalopram	>100
<i>N</i> -Desmethylecitalopram	>100
Fluoxetine	>100
Norfluoxetine	>100
Paroxetine	45
Sertraline	70
Litoxetine	60

IC_{50} is the concentration of the inhibitor which reduces paracetamol formation by 50%.




Fig. 1. The effect of fluvoxamine on the O-deethylation of phenacetin in HL1 (Dixon plots). Phenacetin concentrations: (■) 1 μ M, (▲) 2.5 μ M, (●) 5 μ M, (▼) 10 μ M and (◆) 100 μ M. The lines represent the best fits according to Eqn 1.

MgCl₂, 5 mM). Incubations were carried out at 37° in a shaking water bath in air, and the reactions were stopped after 10 min by adding 100 μ L of ice-cold ZnSO₄ (0.1 M). After centrifugation at 900 g

for 10 min the supernatant was kept at –20° until analysis. Additional experiments were performed with microsomes from HL1 and phenacetin in a final concentration of 10 μ M and seven other SSRIs: citalopram, *N*-desmethylecitalopram, fluoxetine, norfluoxetine, paroxetine, sertraline and litoxetine in final concentrations of 0, 0.01, 0.1, 0.5, 1.0, 10 and 100 μ M. All incubations were carried out in duplicate. Less than 10% of the substrate was consumed during the incubations. Paracetamol formed by O-deethylation of phenacetin was analysed by HPLC with electrochemical detection [15]. Thus, an aliquot (100 μ L) of the incubation mixture was mixed with an equal volume of 2 N perchloric acid. Twenty microlitres of the supernatant were injected into the HPLC column after centrifugation. For measurement of paracetamol a Spherisorb ODS, 5 μ m 15 cm column was eluted with phosphate buffer pH 4.4 (methanol 92/8; v/v) and the conductivity of the effluent was monitored with an ESA ColuChem II electrochemical detector equipped with a 5010 analytical cell set of 150 mV (electrode 1) and 350 mV (electrode 2) and a 0.5 μ A full range deflection. The assay limit of paracetamol was 40 femtomol and the interday coefficient of variation 5%.

RESULTS

A graphical analysis revealed a curvilinear relationship between the reciprocal velocity of the paracetamol formation and the fluvoxamine concentration (Fig. 1). Hence, an equation which describes a two-enzyme model was fitted to the data:

$$V = \frac{V_{\max} \times S}{K_m \left(1 + \frac{C_i}{K_i}\right) + S} + LS. \quad (1)$$

According to this model, the O-deethylation of phenacetin proceeds in parallel via a high-affinity enzyme, alias the CYP1A2, showing inhibition and a low-affinity enzyme showing no inhibition. K_m is the Michaelis constant, V_{\max} is the maximal velocity and K_i is the apparent inhibitor constant for inhibition of the high-affinity site, C_i is the fluvoxamine concentration, S is the phenacetin concentration and L is a constant which relates S to the velocity via the low-affinity enzyme [3]. The equation was fitted to the data using an iterative method [16]. The mean

apparent K_m ranged from 14 to 57 μM and the mean apparent V_{\max} for paracetamol formation in the three human livers, HL1, HL2 and HL3 ranged from 27 to 202 nmol/mg/hr (Table 1). The apparent K_i for fluvoxamine inhibition of the high-affinity O-deethylation of phenacetin ranged from 0.12 to 0.24 μM (Fig. 1 and Table 1). The IC_{50} values of seven other SSRIs ranged from 45 to >100 μM (Table 2).

DISCUSSION

It has previously been shown that the kinetics of phenacetin O-deethylation is biphasic [17–19] and indeed this was confirmed in the present study (Fig. 1). We report apparent K_m values for the high-affinity site (Table 1) which are in agreement with previously published values [17–19].

The present study shows that fluvoxamine is a very potent inhibitor of the formation of paracetamol from phenacetin via the high-affinity site, alias the CYP1A2 function [6, 12]. Our findings ought to be confirmed by studying the effects of fluvoxamine on purified or expressed CYP1A2. The K_i values for O-deethylation (Table 1) are almost identical to the value of 0.14 μM reported for N-demethylation of imipramine [3]. This is consistent with the assumption that the two oxidations are catalysed by the same P450. Also, in agreement with the present study citalopram, N-desmethylcitalopram, fluoxetine and norfluoxetine did not inhibit the N-demethylation of imipramine, and in addition paroxetine is a weak inhibitor of this oxidation [3]. For technical reasons (interfering peaks on the chromatogram) it was not possible to investigate the effects of sertraline and litoxetine on the metabolism of imipramine *in vitro*.

CYP1A2 is a constitutively expressed enzyme which is induced by polycyclic aromatic hydrocarbons [6]. CYP1A2 is a major enzyme activating a number of heterocyclic amines into their proximate carcinogenic and/or mutagenic forms [12]. Recent studies have shown that CYP1A2 also catalyses the oxidation of uroporphyrinogen to uroporphyrin and, hence, that the enzyme may play a role in the development of uroporphyrin [20]. More important in the present context, CYP1A2 is a major enzyme catalysing the biotransformation of a number of drugs such as phenacetin [6, 12], caffeine and theophylline [8] and imipramine [5]. It is suggested that fluvoxamine has the potential for causing important drug–drug interactions when given in combination with either of these drugs. Indeed, this has already been demonstrated for theophylline [9–11] and for imipramine [21]. On the basis of the much weaker *in vitro* inhibition of CYP1A2 reported here (Table 2) it is unlikely that other SSRIs cause similar problems.

Furaphylline which is an antiasthmatic drug of the methylxanthine group is also a potent inhibitor of phenacetin O-deethylation *in vitro* [22], and it has been reported that caffeine accumulates to a toxic level due to potent inhibition of its metabolism in coffee drinking furaphylline-treated volunteers [23]. Similar interaction studies with fluvoxamine and caffeine are warranted.

During concomitant fluvoxamine intake, the

steady-state plasma levels of propranolol, clomipramine and amitriptyline may increase by up to seven times [1, 24]. This suggests that CYP1A2 is a major enzyme catalysing the biotransformation of these drugs. Thus, if the very potent inhibition is specific for CYP1A2 then it is possible that fluvoxamine will become an important tool for the assessment of the role of the isozyme for the oxidation of drugs and other xenobiotics in humans.

Acknowledgements—This study was supported by the Danish Medical Research Council, Grant Nos 12-9206 (K.B.), 12-0282-1 (K.B.) and 12-9374 (H.E.P.). The technical assistance of Mrs Annelise Casa is appreciated.

REFERENCES

1. Benfield P and Ward A, Fluvoxamine—a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. *Drugs* 32: 313–334, 1986.
2. Nebert DW, Nelsen DR, Coon MJ, Estabrook RW, Feyereisen R, Fujii-Kuriyama Y, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Loper JC, Sato R, Waterman MR and Waxman DJ, The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. *DNA Cell Biol* 10: 1–14, 1991.
3. Skjelbo E and Brøsen K, Inhibitors of imipramine metabolism by human liver microsomes. *Br J Clin Pharmacol* 34: 256–261, 1992.
4. Skjelbo E, Brøsen K, Hallas J and Gram LF, The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. *Clin Pharmacol Ther* 49: 18–23, 1991.
5. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Guengerich FP, Beaune P, Maurel P and Leroux JP, The major pathway of imipramine metabolism is catalysed by cytochromes P-450 1A2 and P-450 3A4 in human liver, submitted.
6. Sesardic D, Boobis AR, Edwards RJ and Davies DS, A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. *Br J Clin Pharmacol* 26: 363–372, 1988.
7. Perel JM, Shostak M, Gann E, Kantor SJ and Glassman AH, Pharmacodynamics of imipramine and clinical outcome in depressed patients. In: *Pharmacokinetics of Psychoactive Drugs* (Eds. Gottschalk LA and Merlis S), pp. 229–241. Spectrum Publications, New York, 1976.
8. Campbell ME, Grant DM, Inaba T and Kalow W, Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. *Drug Metab Disp* 15: 237–248, 1987.
9. Diot P, Jonville AP, Gerard F, Bonnelle M, Autret E, Breteau M, Lemane E and Lavandier M, Possible interaction entre theophylline et fluvoxamine. *Therapie* 46: 170–171, 1991.
10. Sperber AD, Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. *Drug Safety* 6: 460–462, 1991.
11. Thomson AH, McGovern EM, Bennie P, Caldwell G and Smith M, Interaction between fluvoxamine and theophylline. *Pharm J* 137, 1st August 1992.
12. Butler MA, Iwasaki M, Guengerich FP and Kadlubar FF, Human cytochrome P-450pa (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. *Proc Natl Acad Sci USA* 86: 7696–7700, 1989.

13. Meier PJ, Mueller HK, Dick B and Meyer UA, Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. *Gastroenterology* **85**: 682–692, 1983.
14. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurement with the Folin phenol reagent. *J Biol Chem* **193**: 265–275, 1951.
15. Loft S, Otton SV, Lennard MS, Tucker GT and Poulsen HE, Characterization of metronidazole metabolism by human liver microsomes. *Biochem Pharmacol* **41**: 1127–1134, 1991.
16. Holford N, *MK Model, Version 4 Biosoft*. Cambridge, U.K., 1990.
17. Boobis AR, Kahn GK, Whyte C, Brodie MJ and Davies DS, Biphasic O-deethylation of phenacetin and 7-ethoxycoumarin by human and rat liver microsomal fractions. *Biochem Pharmacol* **30**: 2451–2456, 1981.
18. Distlerath LM, Reilly PEB, Martin MV, Davis GG, Wilkinson GR and Guengerich FP, Purification and characterization of human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. *J Biol Chem* **260**: 9057–9067, 1985.
19. Gilliam EMJ and Reilly PEB, Phenacetin O-deethylation by human liver microsomes: kinetics and propranolol inhibition. *Xenobiotica* **18**: 95–104, 1988.
20. Lambrecht RW, Sinclair PR, Gorman N and Sinclair JF, Uroporphyrinogen oxidation catalysed by reconstituted cytochrome P450IA2. *Arch Biochem Biophys* **294**: 504–510, 1992.
21. Spina E, Campo GM, Avenoso A, Pollicino MA and Caputi AP, Interaction between fluvoxamine and imipramine/desipramine in four patients. *Ther Drug Monit* **14**: 194–196, 1992.
22. Scsardic D, Boobis AR, Murray BP, Murray S, Segura J, Torre RDL and Davies DS, Furaphylline is a potent selective inhibitor of cytochrome P450IA2 in man. *Br J Clin Pharmacol* **29**: 651–663, 1990.
23. Tarrus E, Cami J, Roberts DJ, Spickett RGW, Celdran E and Segura J, Accumulation of caffeine in healthy volunteers treated with furaphylline. *Br J Clin Pharmacol* **23**: 9–18, 1987.
24. Bertchy G, Vandel S, Vandel B, Allers G and Volmat R, Fluvoxamine-tricyclic antidepressant interaction. *Eur J Clin Pharmacol* **40**: 119–120, 1991.